Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Hydrocortisonbutyrate 0,1 % cutanenous use (class II)

Generic name
Hydrocortisonbutyrate 0,1 % cutanenous use (class II)
Brand name
ATC Code
D07AB02

Pharmacokinetics in children

PK data not reviewed

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Atopic dermatitis
  • Cutaneous
    • 1 month up to 18 years
      [1] [4]
        • Apply to the affected skin once daily according to finger-tip-unit method <insert link to FTU page).
        • Maximum dose: < 2 yrs: 30 g/week; ≥ 2 years: 60 grams/week; adults: no restriction.
        • With improvement, taper to 1once daily dosing for 2-4 days/week.

        Note the difference between hydrocortisone acetate (class I) and hydrocortisone butyrate (class II).

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Prolonged use and use of high doses- especially when the skin is covered with, for example, a diaper -may lead to systemic side effects. (SmPC)

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

In infants, the diaper may act as an occlusive dressing, thereby increasing systemic absorption and leading to systemic effects. Children have a relatively large skin surface area and thin skin. Prolonged use of dermatocorticosteroids on large and damaged skin surfaces can potentially lead to more rapid systemic side effects, adrenal suppression and also growth hormone suppression in them. It is therefore recommended, when long-term application is necessary, that height and weight be monitored regularly.

When applying to the eyelids, careful consideration should be given to the possibility of contamination of the conjunctiva with the risk of developing glaucoma simplex or sub-capsular cataract on the one hand and the risk of corneal damage due to continuous rubbing of untreated exudate on the other hand.

 

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

References

  1. Nederlandse Vereniging voor Dermatologie en Venerelogie, Richtlijn constitutioneel eczeem., 2019
  2. Nederlandse Vereniging voor Dermatologie en Venerelogie, Leidraad Dermatocorticosteroiden, 2019
  3. ZorgInstituut Nederland, Farmacotherapeutisch kompas (Eigenschappen, bijwerkingen, contra-indicaties, waarschuwingen en voorzorgen), Geraadpleegd 28 jun 2021
  4. CHEPLAPHARM Arzneimittel GmbH, SmPC Alfason® 0,1 % Creme (4932.00.00)/Salbe/Cresa/Crinale/Crelo, 03/2021

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes